@article{APS7495,
author = {Fa-lin Yang and Ke-qing Hu and Xin Wang and Zi-mo Liu and Qin Hu and Ji-fu Li and Hong He},
title = {Combination of raloxifene, aspirin and estrogen as novel paradigm of hormone replacement therapy in rabbit model of menopause},
journal = {Acta Pharmacologica Sinica},
volume = {32},
number = {8},
year = {2016},
keywords = {},
abstract = {Aim: To assess a novel hormone replacement therapy (HRT) paradigm using raloxifene, aspirin combined with estrogen in rabbit model of menopause.
Methods: Female New Zealand white rabbits were ovariectomized or sham-operated. The ovariectomized rabbits were divided into 7 groups: estradiol valerate (E2), raloxifene, aspirin, E2 /raloxifene, E2/aspirin, E2 /raloxifene/aspirin and vehicle. Two weeks after the operation, the rabbits were administered the above drugs for 12 weeks. Then, the mammary glands were examined histologically, uterus was weighted, and blood sample was collected for analyzing the levels of estrogen, serum lipids and monocyte chemoattractant protein (MCP)-1, and platelet aggregation. The aortic tissue was examined morphometrically.
Results: Compared with E2 0.1 mg·kg−1·d−1 treatment alone, the pairing of raloxifene 10 mg·kg−1·d−1 with E2 significantly decreased the extent of mammary gland branches and ducts (5.53%±1.23% vs. 15.4%±2.17%, P},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/7495}
}